<?xml version='1.0' encoding='utf-8'?>
<document id="27178732"><sentence text="Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin."><entity charOffset="90-99" id="DDI-PubMed.27178732.s1.e0" text="pazopanib" /><entity charOffset="104-113" id="DDI-PubMed.27178732.s1.e1" text="cisplatin" /><pair ddi="false" e1="DDI-PubMed.27178732.s1.e0" e2="DDI-PubMed.27178732.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27178732.s1.e0" e2="DDI-PubMed.27178732.s1.e1" /></sentence><sentence text="We hypothesized that pazopanib is an inhibitor of cisplatin renal transporters OCT2, MATE1 and MATE2-K based on previous studies demonstrating an interaction between tyrosine kinase inhibitors and these transporters"><entity charOffset="21-30" id="DDI-PubMed.27178732.s2.e0" text="pazopanib" /><entity charOffset="50-59" id="DDI-PubMed.27178732.s2.e1" text="cisplatin" /><entity charOffset="166-174" id="DDI-PubMed.27178732.s2.e2" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.27178732.s2.e0" e2="DDI-PubMed.27178732.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27178732.s2.e0" e2="DDI-PubMed.27178732.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27178732.s2.e0" e2="DDI-PubMed.27178732.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27178732.s2.e1" e2="DDI-PubMed.27178732.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27178732.s2.e1" e2="DDI-PubMed.27178732.s2.e2" /></sentence><sentence text=" Because several combinations of targeted therapies and cytotoxics are currently in development for cancer treatment, such an interaction is worth investigating" /><sentence text=" Experiments on HEK293 cells stably transfected to express OCT2, MATE1, MATE2-K or an empty vector (EV) were conducted" /><sentence text=" The inhibitory effect of pazopanib on these transporters was measured using the uptake of fluorescent substrate ASP+ and cisplatin in the different cell lines"><entity charOffset="26-35" id="DDI-PubMed.27178732.s5.e0" text="pazopanib" /><entity charOffset="122-131" id="DDI-PubMed.27178732.s5.e1" text="cisplatin" /><pair ddi="false" e1="DDI-PubMed.27178732.s5.e0" e2="DDI-PubMed.27178732.s5.e0" /><pair ddi="false" e1="DDI-PubMed.27178732.s5.e0" e2="DDI-PubMed.27178732.s5.e1" /></sentence><sentence text=" The effect of pazopanib on cisplatin-induced cytotoxicity was also evaluated"><entity charOffset="15-24" id="DDI-PubMed.27178732.s6.e0" text="pazopanib" /><entity charOffset="28-37" id="DDI-PubMed.27178732.s6.e1" text="cisplatin" /><pair ddi="false" e1="DDI-PubMed.27178732.s6.e0" e2="DDI-PubMed.27178732.s6.e0" /><pair ddi="false" e1="DDI-PubMed.27178732.s6.e0" e2="DDI-PubMed.27178732.s6.e1" /></sentence><sentence text=" A decrease of ASP+ uptake was observed in OCT2-HEK, MATE1-HEK and MATE2K-HEK cell lines after addition of pazopanib at increasing concentrations"><entity charOffset="107-116" id="DDI-PubMed.27178732.s7.e0" text="pazopanib" /></sentence><sentence text=" Pazopanib inhibited cisplatin specific uptake in OCT2-HEK, MATE1-HEK and MATE2K-HEK lines"><entity charOffset="1-10" id="DDI-PubMed.27178732.s8.e0" text="Pazopanib" /><entity charOffset="21-30" id="DDI-PubMed.27178732.s8.e1" text="cisplatin" /><pair ddi="false" e1="DDI-PubMed.27178732.s8.e0" e2="DDI-PubMed.27178732.s8.e0" /><pair ddi="false" e1="DDI-PubMed.27178732.s8.e0" e2="DDI-PubMed.27178732.s8.e1" /></sentence><sentence text=" Cytotoxicity experiments showed that co-incubation of cisplatin with pazopanib multiplied up to 2"><entity charOffset="55-64" id="DDI-PubMed.27178732.s9.e0" text="cisplatin" /><entity charOffset="70-79" id="DDI-PubMed.27178732.s9.e1" text="pazopanib" /><pair ddi="false" e1="DDI-PubMed.27178732.s9.e0" e2="DDI-PubMed.27178732.s9.e0" /><pair ddi="false" e1="DDI-PubMed.27178732.s9.e0" e2="DDI-PubMed.27178732.s9.e1" /></sentence><sentence text="7, 2" /><sentence text="4 and 1" /><sentence text="6 times the EC50 values of cisplatin in OCT2-HEK, MATE1-HEK and MATE2K-HEK cell lines respectively, reaching about the same values as in EV-HEK cells"><entity charOffset="27-36" id="DDI-PubMed.27178732.s12.e0" text="cisplatin" /></sentence><sentence text=" To conclude, pazopanib inhibits OCT2, MATE1 and MATE2-K, which are involved in cisplatin secretion into urine"><entity charOffset="14-23" id="DDI-PubMed.27178732.s13.e0" text="pazopanib" /><entity charOffset="80-89" id="DDI-PubMed.27178732.s13.e1" text="cisplatin" /><pair ddi="false" e1="DDI-PubMed.27178732.s13.e0" e2="DDI-PubMed.27178732.s13.e0" /><pair ddi="false" e1="DDI-PubMed.27178732.s13.e0" e2="DDI-PubMed.27178732.s13.e1" /></sentence><sentence text=" The combination of these two drugs may lead to an interaction and increase the cisplatin-induced systemic toxicity"><entity charOffset="80-89" id="DDI-PubMed.27178732.s14.e0" text="cisplatin" /></sentence><sentence text=" Given the wide variability of plasma pazopanib concentrations observed in vivo, the interaction may occur in a clinical setting, particularly in overexposed patients"><entity charOffset="38-47" id="DDI-PubMed.27178732.s15.e0" text="pazopanib" /></sentence><sentence text=" The existence of a drug-drug interaction should be investigated when pazopanib is associated with a substrate of these transporters"><entity charOffset="70-79" id="DDI-PubMed.27178732.s16.e0" text="pazopanib" /></sentence><sentence text="" /></document>